Recombinant Human TGF-beta 2, ACFP Protein

  • Purity
    >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
  • Endotoxin Level
    <0.10 EU per 1 μg of the protein by the LAL method.
  • Activity
    Measured by its ability to inhibit the IL-4-dependent proliferation of HT‑2 mouse T cells. Tsang, M. et al. (1995) Cytokine 7:389. The ED50 for this effect is typically 0.025-0.25 ng/mL.
  • Source
    Spodoptera frugiperda, Sf 9 (baculovirus)-derived Ala303-Ser414 Accession # P61812 Produced in an animal component free process (ACFP).
  • Accession #
  • N-terminal Sequence
  • Predicted Molecular Mass
    12.7 (monomer) kDa
    9-11 kDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA.
Reconstitution Reconstitute at 100 μg/mL in sterile 4 mM HCl
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Data Images
TGF‑ beta 2 Suppresses IL-4-induced Proliferation. 
Recombinant Human Animal Component Free (ACFP) TGF‑ beta 2 inhibits IL-4-induced proliferation of HT‑2 mouse T cells. The ED50 for this effect is typically 0.025-0.25 ng/mL.
1 μg/lane of Recombinant HumanTGF-beta 2 (Catalog # ACFP302) was resolved with SDS-PAGE under reducing (R) andnon-reducing (NR) conditions and visualized by silver staining, showing bandsat 12.1 and 23.4 kDa, respectively.
Background: TGF-beta 2

TGF-beta 2 (transforming growth factor beta 2) is one of three closely related mammalian members of the large TGF-beta  superfamily that share a characteristic cysteine knot structure (1 - 7). TGF-beta 1, -2 and -3 are highly pleiotropic cytokines proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1 - 4). Each TGF-beta isoform has some non-redundant functions; for TGF-beta 2, mice with targeted deletion show defects in development of cardiac, lung, craniofacial, limb, eye, ear and urogenital systems (2). Human TGF-beta 2 cDNA encodes a 414 amino acid (aa) precursor that contains a 19 aa signal peptide and a 395 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 232 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-  beta 2 (8, 9). Disulfide-linked homodimers of LAP and TGF-beta 2 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex (8 - 10). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-beta 2 shows 100% aa identity with porcine, canine, equine and bovine TGF-beta 2, and 97% aa identity with mouse and rat TGF-beta 2. It demonstrates cross-species activity (1). TGF-beta 2 signaling begins with binding to a complex of the accessory receptor betaglycan (also known as TGF-beta  RIII) and a type II ser/thr kinase receptor termed TGF-beta  RII. This receptor then phosphorylates and activates another ser/thr kinase receptor, TGF-beta  RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1. The whole complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Use of other signaling pathways that are Smad-independent allows for disparate actions observed in response to TGF-beta in different contexts (11).

  • References:
    1. Sporn, M.B. (2006) Cytokine Growth Factor Rev. 17:3.
    2. Dunker, N. and K. Krieglstein, 2000, Eur. J. Biochem. 267:6982.
    3. Wahl, S.M. (2006) Immunol. Rev. 213:213.
    4. Chang, H. et al. (2002) Endocr. Rev. 23:787.
    5. Lin, J.S. et al. (2006) Reproduction 132:179.
    6. Hinck, A.P. et al. (1996) Biochemistry 35:8517.
    7. Mittl, P.R.E. et al. (1996) Protein Sci. 5:1261.
    8. deMartin, R. et al. (1987) EMBO J. 6:3673.
    9. Miyazono, K. et al. (1988) J. Biol. Chem. 263:6407.
    10. Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
    11. de Caestecker, M. et al. (2004) Cytokine Growth Factor Rev. 15:1.
    12. Zuniga, J.E. et al. (2005) J. Mol. Biol. 354:1052.
  • Long Name:
    Transforming Growth Factor beta 2
  • Entrez Gene IDs:
    7042 (Human); 21808 (Mouse); 397084 (Porcine)
  • Alternate Names:
    BSC-1 cell growth inhibitor; cetermin; Glioblastoma-derived T-cell suppressor factor; G-TSF; MGC116892; polyergin; TGFB2; TGFbeta 2; TGF-beta2; TGF-beta-2; transforming growth factor beta-2; transforming growth factor, beta 2
Related Research Areas

Have you used Recombinant Human TGF-beta 2, ACFP Protein?

Submit a review and receive a $25 amazon gift card if you include an image - $10 Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

    Contact Information

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Certificate of Analysis Lookup

The document you requested is not available online. Please enter the Catalog Number and Lot Number below to have a document emailed to you at the address provided

Certificate of Analysis Lookup

Research Areas of Interest
R&D Systems Guarantee


Customer Information